Associate Scientist/Scientist, Immuno-Oncology Discovery

Job ID
Research & Development

Role / Responsibilities

The successful candidate will be an experienced bench scientist engaged in the discovery and testing of novel cancer immunotherapeutic biologics. Responsibilities include designing, developing, and conducting experiments aimed at identifying optimal therapeutic candidates and understanding the mechanism of action of our therapeutic molecules (mostly monoclonal antibodies). S/he will have the opportunity to work independently and collaboratively to advance portfolio programs in a dynamic and fast-paced environment.


Assay systems will include: multi-color flow cytometry, ELISA and multiplex technologies, proliferation assays, quantitative PCR, and primary immune cell isolation. S/he will be responsible for data analysis, thorough documentation of work, and clear communication of results in group settings.


  • B.S./M.S. in biology, biochemistry, immunology or related discipline with a minimum of 4+ years of industry experience or Ph.D. with applicable bench research
  • A working knowledge of fundamental immunological principles
  • Extensive experience with cell-based assays using primary cells and ex vivo analyses such as MLR, and T cell activation/proliferation assays. 
  • Hands-on experience with: flow cytometry, isolation and manipulation of human blood and blood components, in vitro functional assays, multiplex ELISA systems.
  • Excellent organizational, communication and presentation skills
  • Deadline-driven, results oriented approach to advance programs according to timelines
  • Able to thrive in a highly collaborative, fast-paced, team-oriented environment with colleagues from diverse disciplines but with the capacity to work independently.
  • Ability to think creatively and critically to make a measurable impact on projects is an important aspect of this role.

To apply, please visit our website at 


Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed